head title

"The most active body healing peptide available!"

Elite soldiers and athletes use it to recover and heal wounds TWICE faster! link to buy
But it's also used for ulcers, burns, sprains, etc...
it simply signals the body to accelerate any healing process!

Pro-Healer or BPC 157 is an external and internal healing protein, oral and topical, applied to external sores, cuts and abrasions, will increase healing time dramatically.
Studies have shown that BPC157, taken orally, 1mg daily, can help to reverse ulcer damage, reduce inflammation through out the digestive tract and heal liver from alcohol and other damage among other things.
The trials and potential uses for this protein are endless and continuing!

Protective effects of pentadecapeptide BPC 157 on gastric ulcer

This trial shows the power of BPC157 to repair ulcer gastric damages!

 

World Journal of Gastroenterol 

2004 April 1

Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
AIM:
To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods.

METHODS:
Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers.

RESULTS:
Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control).

CONCLUSION:
Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer.

The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.

 

Source of this article: http://www.wjgnet.com/1007-9327/10/1032.asp

or http://www.ncbi.nlm.nih.gov/pubmed/15052688?dopt=Abstract

 

Useful references:

  • 1. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Jagic V, Turkovic B, Mildner B, Duvnjak M. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Physiol Hung 1992; 80: 89-98
  • 2. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993; 87: 313-327
  • 3. Prkacin I, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Staresinic M, Anic T, Mikus D, Sikiric P, Seiwerth S, Mise S, Rotkvic I, Jagic V, Rucman R, Petek M, Turkovic B, Marovic A, Sebecic B, Boban-Blagaic A, Kokic N. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris 2001; 95: 315-324
  • 4. Stancic-Rokotov D, Slobodnjak Z, Aralica J, Aralica G, Perovic D, Staresinic M, Gjurasin M, Anic T, Zoricic I, Buljat G, Prkacin I, Sikiric P, Seiwerth S, Rucman R, Petek M, Turkovic B, Kokic N, Jagic V, Boban-Blagaic A. Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. J Physiol Paris 2001; 95: 303-308
  • 7. Sikiric P, Seiwerth S, Grabarevic Z, Balen I, Aralica G, Gjurasin M, Komericki L, Perovic D, Ziger T, Anic T, Prkacin I,
    Separovic J, Stancic-Rokotov D, Lovric-Bencic M, Mikus D, Staresinic M, Aralica J, DiBiaggio N, Simec Z, Turkovic B,
    Rotkvic I, Mise S, Rucman R, Petek M, Sebecic B, Ivasovic Z, Boban-Blagaic A, Sjekavica I. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol Paris 2001; 95: 261-270
  • 8. Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns
    2001; 27: 817-827
  • 9. Prkacin I, Aralica G, Perovic D, Separovic J, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Ziger T, Anic T, Sikiric P,
    Seiwerth S, Staresinic M, Mise S, Rotkvic I, Jagic V, Rucman R, Petek M, Turkovic B, Marovic A, Sjekavica I, Sebecic B,
    Boban-Blagaic A, Ivasovic Z. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent,
    attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris 2001;95:295-301
  • 10. Bilic I, Zoricic I, Anic T, Separovic J, Stancic-Rokotov D, Mikus D, Buljat G, Ivankovic D, Aralica G, Prkacin I, Perovic D,
    Mise S, Rotkvic I, Petek M, Rucman R, Seiwerth S, Sikiric P. Haloperidol-stomach lesions attenuation by
    pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine,
    cimetidine and misoprostol in mice. Life Sci 2001; 68: 1905-1912
  • 11. Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, Stancic-Rokotov D, Separovic J, Seiwerth S, Grabarevic Z,
    Rucman R, Petek M, Ziger T, Sebecic B, Zoricic I, Turkovic B, Aralica G, Perovic D, Duplancic B, Lovric-Bencic M,
    Rotkvic I, Mise S, Jagic V, Hahn V. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease
    models in mice and gastric lesions induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrophyridine. J Physiol Paris
    1999; 93: 505-512
  • 12. Petek M, Sikiric P, Anic T, Buljat G, Separovic J, Stancic-Rokotov D, Seiwerth S, Grabarevic Z, Rucman R, Mikus D, Zoricic
    I, Prkacin I, Sebecic B, Ziger T, Coric V, Turkovic B, Aralica G, Rotkvic I, Mise S, Hahn V. Pentadecapeptide BPC 157
    attenuates gastric lesions induced by alloxan in rats and mice. J Physiol Paris 1999; 93: 501-504
  • 13. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S. The beneficial
    effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress,
    cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut
    peptides. Life Sci 1994; 54: PL63-68
  • 14. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, Zoricic I, Ferovic D, Aralica G, Buljat G, Prkacin I,
    Lovric-Bencic M, Separovic J, Seiwerth S, Rucman R, Petek M, Turkovic B, Ziger T. Anxiolytic effect of BPC-157, a gastric
    pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin 2001; 22: 225-230
  • 15. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Marovic A, Prkacin I, Duplancic B, Zoricic I, Aralica G,
    Lovric-Bencic M, Ziger T, Perovic D, Rotkvic I, Mise S, Hanzevacki M, Hahn V, Seiwerth S, Turkovic B, Grabarevic Z,
    Petek M, Rucman R. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic
    unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris 2000; 94: 99-104
  • 16. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M,
    Marovic A, Rucman R, Petek M, Zoricic I, Ziger T, Aralica G, Konjevoda P, Prkacin I, Gjurasin M, Miklic P, Artukovic B,
    Tisljar M, Bratulic M, Mise S, Rotkvic I. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate
    on new vessels and new granulation tissue formation. J Physiol Paris 1999; 93: 479-485
  • 17. Sebecic B, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, Grabarevic Z, Rucman R, Petek M, Konjevoda P, Jadrijevic S,
    Perovic D, Slaj M. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in
    rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone 1999; 24: 195-202
  • 18. Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, Seiwerth S, Mise S, Turkovic B, Dodig G, Miklic P, Buljat G,
    Prkacin I. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and
    gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31
  • 19. Sikiric P, Seiwerth S, Deskovic S, Grabarevic Z, Marovic A, Rucman R, Petek M, Konjevoda P, Jadrijevic S, Sosa T,
    Perovic D, Aralica G, Turkovic B. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Eur J Pharmacol 1999; 364: 23-31
  • 20. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, Zoricic I, Rak D, Perovic D, Aralica G, Buljat G,
    Prkacin I, Lovric-Bencic M, Separovic J, Seiwerth S, Rucman R, Petek M, Turkovic B, Ziger T, Boban-Blagaic A,
    Bedekovic V, Tonkic A, Babic S. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior
    disturbances. Acta Pharmacol Sin 2002; 23: 412-422
  • 21. Sikiric P, Jadrijevic S, Seiwerth S, Sosa T, Deskovic S, Perovic D, Aralica G, Grabarevic Z, Rucman R, Petek M, Jagic V,
    Turkovic B, Ziger T, Rotkvic I, Mise S, Zoricic I, Sebecic B, Patrlj L, Kocman B, Sarlija M, Mikus D, Separovic J,
    Hanzevacki M, Gjurasin M, Miklic P. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or
    cholestyramine application in reflux oesophagitis in rats. J Physiol Paris 1999; 93: 467-477
  • 22. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Duplancic B, Marovic A, Zoricic I, Prkacin I,
    Lovric-Bencic M, Aralica G, Ziger T, Perovic D, Jelovac N, Dodig G, Rotkvic I, Mise S, Seiwerth S, Turkovic B,
    Grabarevic Z, Petek M, Rucman R. Gastric mucosal lesions induced by complete dopamine system failure in rats. The
    effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. J Physiol Paris
    2000; 94: 105-110
  • 23. Jelovac N, Sikiric P, Rucman R, Petek M, Perovic D, Marovic A, Anic T, Seiwerth S, Mise S, Pigac B, Duplancie B,
    Turkovic B, Dodig G, Prkacin I, Stancic-Rokotov D, Zoricic I, Aralica G, Sebecic B, Ziger T, Slobodnjak Z. The effect of a
    novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated
    administration of diazepam. Chin J Physiol 1999; 42: 171-179